Management Appointment

Physiomics PLC
14 February 2008

                 Physiomics plc ('Physiomics' or 'the Company')

14 February 2008



Appointment of Group Financial Controller and Company Secretary


Physiomics plc is pleased to announce the appointment of Mr. Roger John Jones as
Group Financial Controller and Company Secretary. Mr. Jones has for 30 years
been a Fellow of the Association of Chartered Certified Accountants and has held
a number of senior financial positions and key roles in biotechnology and
pharmaceutical companies including Cambridge Antibody Technology, Onyvax,
Archimedes Pharma, Angel Biotechnology and Provensis. Commenting on this
announcement, Physiomics' Chairman, Dr Paul Harper, said:



 'I am delighted that Roger has agreed to join the Company in these capacities.
He brings a wide range of experience to Physiomics and his considerable
experience in the biotech sector make him an especially valuable addition to the
executive team. We have already worked together on a number of projects and I
know first hand what he will be able to contribute to the financial, commercial
and strategic management of the business.'



For further information:

Physiomics plc                                     [phone]
Dr Paul Harper
E-mail: [e-mail]



Grant Thornton Corporate Finance                   [phone]
Philip Secrett, Colin Aaronson



About Physiomics plc

Physiomics plc (AIM:PYC) is a computational systems biology services company
applying simulations of cell behaviour to drug development to reduce the high
attrition rates of clinical trials. As 80-90 per cent of all clinical drug
candidates fail to reach the market, estimates1 show that an overall ten per
cent improvement in success rates could reduce the cost of one drug's
development by as much as $242 million, from the current estimate of around $800
million.

Physiomics develops computational systems biology models to predict and
understand cancer drug efficacy from pre-clinical research to clinical
development. Physiomics has created detailed mathematical models incorporating
most important molecular events taking place during the human cell cycle and
apoptosis processes. Physiomics developed SystemCell(R) technology, a
multi-cellular environment software, which enables the simulation of population
of 'virtual cells'.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in
2004. For further information, please visit www.physiomics-plc.com



SystemCell(R) is a registered trademark of Physiomics plc

1Tufts Centre Impact Report 2002




                      This information is provided by RNS
            The company news service from the London Stock Exchange